摘要
目的:系统评价射频消融(RFA)联合肝动脉栓塞化疗(TACE)治疗原发性肝癌(hepatocellular carci-noma,HCC)的临床疗效。方法:计算机检索Cochrane Library、PubMed、中国知网数据库、中国生物医学文献数据库、中文科技期刊全文数据库,检索时间从数据库建库至2011年12月20日,同时辅助其它检索,纳入RFA联合TACE治疗HCC的临床对照试验。评价纳入研究的质量并提取资料,并用RevMan 5.1软件进行统计分析。结果:共纳入14篇临床对照试验,分析结果显示:与单纯TACE相比,TACE联合RFA能提高HCC治疗的有效率(RR=1.21,95%CI:1.13-1.31,P<0.001)和肿瘤完全坏死率(RR=1.95,95%CI:1.22-3.10,P=0.005),提高AFP转阴率(RR=2.13,95%CI:1.04-4.38,P=0.04)及患者1年(RR=1.38,95%CI:1.18-1.60,P<0.0001)、2年(RR=1.6 6,9 5%CI:1.3 9-1.9 9,P<0.0 0 0 0 1)、3年(RR=2.11,95%CI:1.57-2.84,P<0.00001)生存率,降低癌症复发率(RR=0.55,95%CI:0.33-0.91,P=0.02)。结论:TACE联合RFA可提高HCC治疗有效率和生存率,降低复发率,值得临床推广使用。
Objective：To evaluate the efficacy of RFA combining TACE for patients with primary hepatocellular carcinoma.Methods： Cochrane library,PubMed,CBM,CNKI and VIP were searched.The search was finished in December 20,2011.RCTs of RFA plus TACE for primary hepatocellular carcinoma were included,the quality of included studies were evaluated and analyzed by RevMan 5.1.Results：Fourteen RCTs involving 1579 patients were included.Meta analysis results suggested that compared with TACE alone,RFA plus TACE had a statistically significant benefit in healing efficacy（RR=1.21,95%CI：1.13-1.31,P0.001）,improving tumor＇s completely necrosis（RR=1.95,95%CI：1.22-3.10,P=0.005）,the decline in AFP（RR=2.13,95%CI：1.04-4.38,P=0.04）,and improving survival periods of 1（RR=1.38,95%CI：1.18-1.60,P0.0001）,2（RR=1.66,95%CI：1.39-1.99,P0.00001） and 3（RR=2.11,95%CI：1.57-2.84,P0.00001） years.Reducing recurrence of the cancer（RR=0.55,95%CI：0.33-0.91,P=0.02）.Conclusion：Compared with TACE alone,the RFA plus TACE could significantly improve the efficiency and survival period,and reduce the recurrence.
出处
《现代肿瘤医学》
CAS
2013年第6期1285-1288,共4页
Journal of Modern Oncology
关键词
原发性肝癌
射频消融
肝动脉栓塞化疗
META分析
primary hepatocellular carcinoma
radiofrequency ablation
transcatheter hepatic arterial chemoembolization
Meta analysis
